Updates are available Correction dated 2018-01-12
Click to view Correction: https://doi.org/10.1186/s13073-018-0516-7
-
Authors
Ridge, Perry G.
,
Karch, Celeste M.
Hsu, Simon
Arano, Ivan
Teerlink, Craig C.
Ebbert, Mark T. W.
Gonzalez Murcia, Josue D.
Farnham, James M.
Damato, Anna R.
Allen, Mariet
Wang, Xue
Harari, Oscar
Fernandez, Victoria M.
Guerreiro, Rita
Bras, Jose
Hardy, John
Munger, Ronald
Norton, Maria
Sassi, Celeste
Singleton, Andrew
Younkin, Steven G.
Dickson, Dennis W.
Golde, Todd E.
Price, Nathan D.
Ertekin-Taner, Nilüfer
Cruchaga, Carlos
Goate, Alison M.
Corcoran, Christopher
Tschanz, JoAnn
Cannon-Albright, Lisa A.
Kauwe, John S. K.
-
Funding
Funding for this research was provided by:
National Institute on Aging (RF1AG054052, U01AG052411)
National Institute of Neurological Disorders and Stroke (R01NS080820)
- License Information
-
More Information
Article History
Received: 21 June 2017
Accepted: 27 October 2017
First Online: 29 November 2017
Change Date: 12 January 2018
Change Type: Correction
Change Details: The original version of this article [1] unfortunately contained a typographical error. The ‘Alzheimer’s Disease Neuroimaging Initiative’ was erroneously included as ‘Alzheimer’s Disease Neuroimaging Initative’ in the author list of the article.
Ethics approval and consent to participate
: All research reported in this manuscript complies with the Declaration of Helsinki and was approved by the Brigham Young University Institutional Review Board (approval number E110252) and Utah State University Institutional Review Board (approval number CCSMHA5). Informed consent was obtained from all study participants.
: Not applicable.
: ADNI has received some funding from the following companies: Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. Private sector contributions were facilitated by the Foundation for the National Institutes of Health (ExternalRef removed). Donors retain no rights to discoveries and are not included in discussions of results or publication decisions. As such, these contributions do not represent a conflict of interest. The remaining authors declare that they have no competing interests
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
